Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
复制标题
DOI：
10.1186/1471-2407-12-349
复制
发表时间：
2012-08-09
期刊：
影响因子：
3.8
通讯作者：
Tannapfel A
中科院分区：
文献类型：
--
作者：
Reinacher-Schick A;Schulmann K;Modest DP;Bruns N;Graeven U;Jaworska M;Greil R;Porschen R;Arnold D;Schmiegel W;Tannapfel A
评估 KRAS 密码子 13 突变对接受奥沙利铂和氟嘧啶治疗的晚期结直肠癌 (晚期 CRC) 患者的价值。对来自一项随机 III 期试验的 201 名晚期 CRC 患者的肿瘤标本进行了回顾性分析，该试验比较了奥沙利铂/5-FU 与奥沙利铂/卡培他滨的 KRAS 突变。突变数据与反应数据（总体反应率，ORR）、无进展生存期（PFS）和总生存期（OS）相关。对 201 名患者进行了 KRAS 突变分析（61.2% 为男性；平均年龄 64.2±8.6 岁）。在 36.3% 的肿瘤中发现了 KRAS 突变（28.8% 在密码子 12 中，7.4% 在密码子 13 中）。与密码子 12 和野生型患者相比，密码子 13 患者的 ORR 显着降低 (p = 0.008)。与突变型患者相比，KRAS 野生型患者的总体生存率有更好的趋势 (p = 0.085)。所有患者的 PFS 在三个 KRAS 基因组中没有差异 (p = 0.72)。然而，我们发现密码子 12 和 13 突变肿瘤患者接受输注 5-FU 治疗与基于卡培他滨的治疗方案相比，PFS 存在显着差异。我们的数据表明，在不添加单克隆抗体的奥沙利铂联合化疗下，KRAS 突变的类型可能具有临床相关性，特别是当总体缓解率很重要时。 2002-04-017
To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines. Tumor specimens from 201 patients with advanced CRC from a randomized, phase III trial comparing oxaliplatin/5-FU vs. oxaliplatin/capecitabine were retrospectively analyzed for KRAS mutations. Mutation data were correlated to response data (Overall response rate, ORR), progression-free survival (PFS) and overall survival (OS). 201 patients were analysed for KRAS mutation (61.2% males; mean age 64.2 ± 8.6 years). KRAS mutations were identified in 36.3% of tumors (28.8% in codon 12, 7.4% in codon 13). The ORR in codon 13 patients compared to codon 12 and wild type patients was significantly lower (p = 0.008). There was a tendency for a better overall survival in KRAS wild type patients compared to mutants (p = 0.085). PFS in all patients was not different in the three KRAS genetic groups (p = 0.72). However, we found a marked difference in PFS between patients with codon 12 and 13 mutant tumors treated with infusional 5-FU versus capecitabine based regimens. Our data suggest that the type of KRAS mutation may be of clinical relevance under oxaliplatin combination chemotherapies without the addition of monoclonal antibodies in particular when overall response rates are important. 2002-04-017
登录
查看更多内容
宇宙（癌症中的体细胞突变目录）数据库和网站。
影响因子：
8.8
作者：
Bamford, S;Dawson, E;Forbes, S;Clements, J;Pettett, R;Dogan, A;Flanagan, A;Teague, J;Futreal, PA;Stratton, MR;Wooster, R
通讯作者：
Wooster, R
影响因子：
10.3
作者：
Ince, WL;Jubb, AM;Koeppen, H
通讯作者：
Koeppen, H
影响因子：
45.3
作者：
Moosmann, Nicolas;von Weikersthal, Ludwig Fischer;Heinemann, Volker
通讯作者：
Heinemann, Volker
影响因子：
45.3
作者：
Porschen, Rainer;Arkenau, Hendrik-Tobias;Schmoll, Hans-Joachim
通讯作者：
Schmoll, Hans-Joachim
影响因子：
11.5
作者：
Etienne-Grimaldi, Marie-Christine;Formento, Jean-Louis;Milano, Gerard
通讯作者：
Milano, Gerard